Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Monday . The stock had previously closed at $44.75, but opened at $42.11. Zealand Pharma A/S shares last traded at $42.11, with a volume of 110 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Up 3.9%

The firm’s 50-day simple moving average is $47.45 and its 200 day simple moving average is $54.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The company has a market cap of $3.13 billion, a P/E ratio of 3.25 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The business had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. On average, research analysts forecast that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.